Web12 apr. 2024 · HMPL-306, un double inhibiteur de mIDH1/mIDH2, développé par HUTCHMED, est en cours d'évaluation dans des essais cliniques (NCT04272957, NCT04762602, NCT04764474). WebHUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the …
HUTCHMED (NASDAQ:HCM) Trading 11.1% Higher - Defense World
Web2 dagen geleden · -- Hutchmed will present data related to five of its investigational drug candidates at a cancer research forum in Florida from Friday through Wednesday next week. The company will present data... April 12, 2024 WebHutchmed Stock Forecast FAQ. What is HCM's forecast return on equity (ROE) for 2024-2026? (NASDAQ: HCM) forecast ROE is N/A, which is considered weak.If you're new to stock investing, here's how to buy Hutchmed stock. What is HCM's forecast return on assets (ROA) for 2024-2026? g flashlight\\u0027s
HUTCHMED (China) Limited (HCM) Stock Price, Quote & News
Web6 apr. 2024 · Get HUTCHMED (China) Ltd (13-HK:Hong Kong Stock Exchange) real-time stock quotes, news, price and financial information from CNBC. Web30 mrt. 2024 · Hutchmed Stock Price Today (NASDAQ: HCM) Quote, Market Cap, Chart WallStreetZen Hutchmed Ltd Stock Add to Watchlist Overview Earnings Dividend Ownership $13.64 -0.17 (-1.23%) Updated Mar 28, 2024 1W - 9.07% 1M - 17.58% 3M - 7.02% 1Y - 26.59% HCM Price $13.64 Fair Value Price $15.81 Market Cap $2.36B 52 … WebStock Symbol HCM Investments 2 Share Price $3.31 (As of Thursday Closing) General Information Description HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. christoph maybach